fashion -WSS

fashion

author：explore 2025-10-01 14:15:47 - browse：4858

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： UnitedHealth, Optum discontinue NaviHealth name

hotspot

WSS

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

FDA clears Verve to begin U.S. study of gene

Roche drug slashes death risk in early

Is there really a nursing shortage in the U.S.?

Judge rejects Trump's counterclaim against E. Jean Carroll

Former Georgia lieutenant governor says he received grand jury subpoena

knowledge

fashion

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Astronauts get first look at the spacecraft that will fly them around the moon

23andMe had bad news about my health. I wish a person had delivered it

Hospitals use virtual reality to design more inclusive rooms for kids

State Dept. review finds Biden bears some blame for Afghanistan failures

Smaller biotechs seek to piggyback on weight loss drug boom

Heart attack and stroke risk calculators need revising

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

As demand for Covid shots wanes, Moderna seeks its next success

Smaller biotechs seek to piggyback on weight loss drug boom

entertainment

J&J lung cancer data amount to new salvo against AstraZeneca

STAT Summit: How researchers deal with rejection

The problems with dementia villages

Germany receives 178 compensation applications from gay servicepeople over discrimination

FTX founder Sam Bankman

STAT Summit: The economic case for universal basic health care

Wikipedia

hotspot

leisure time

focus